Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors

Lonza AG Acquires PharmaCell BV

June 1, 2017

Biotechnology

Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.

Galapagos NV Acquires CellPoint and AboundBio

June 21, 2022

Biotechnology

Galapagos NV has acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies, combining CellPoint's decentralized point-of-care CAR-T manufacturing platform with AboundBio's fully human antibody discovery capabilities. The deal includes an upfront €125 million for CellPoint (plus up to €100 million in milestones) and $14 million for AboundBio, positioning Galapagos to expand its cell therapy pipeline and validate a rapid vein-to-vein delivery model.

Catalent Acquires Delphi Genetics to Add Plasmid DNA Capabilities

February 23, 2021

Biotechnology

Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.

Great Point Partners Makes Growth Investment in iXCells Biotechnologies

September 29, 2022

Biotechnology

Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.

HealthQuest Capital and Great Point Partners Invest Growth Equity in Cellipont Bioservices; Darren Head Named CEO

October 7, 2024

Biotechnology

Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.

Title21 Health Solutions Acquires MyCellHub

January 8, 2026

Cloud & SaaS

Title21 Health Solutions, an ArchiMed portfolio company, has acquired Belgium-based MyCellHub to integrate a cloud-based Manufacturing Execution System (MES) into its life-sciences quality management and orchestration platform. The add-on expands Title21's end-to-end offering for cell and gene therapy manufacturing, strengthens compliance and real-time production monitoring capabilities, and extends the company's geographic reach into Europe. Financial terms were not disclosed.